Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 16/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779571 | 0.88 | JAK2 (0.42) | KDM4ESMN1; SMN2KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL23779558 | 0.85 | OPRK1 (0.49) | OPRK1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21171745 | 0.75 | OPRK1 (0.76) | OPRK1KDM4EKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL23779555 | 0.75 | OPRK1 (0.49) | OPRK1KDM4EKMT2AALDH1A1 | |
| SCHEMBL21171716 | 0.75 | OPRK1 (0.73) | OPRK1 | |
| SCHEMBL23779532 | 0.75 | SCN10A (0.44) | OPRK1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20878468 | 0.74 | MAP3K5 (0.54) | OPRK1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23779674 | 0.73 | HSD17B10 (0.40) | OPRK1KDM4ENPSR1KMT2AALDH1A1 | |
| SCHEMBL31343813 | 0.73 | SCN10A (0.62) | OPRK1 | |
| SCHEMBL21170887 | 0.73 | OPRK1 (0.76) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119363-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3873468-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119363-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | OPRK1 372/4885KDM4E 3634/4885NPC1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.